Skip to main content
. 2022 May;14(5):1332–1341. doi: 10.21037/jtd-21-1973

Figure 3.

Figure 3

Changes in inflammatory marker levels and pulmonary function. The solid and long dashed lines represent patients treated with tocilizumab and steroids, respectively. A permutation test was used. LRG, leucine-rich α2-glycoprotein; CRP, C-reactive protein; %VC, percent vital capacity of the predicted normal value; %DLco, percent diffusing capacity of the lung for carbon monoxide.